Cellectis S.A.’s Q4 2024 Earnings Conference Call: Insights from the CEO and Executive Team
On March 14, 2025, Cellectis S.A. (NASDAQ: CLLS ) held its Full Year 2024 Earnings Conference Call. The call was led by Arthur Stril, the CFO and Chief Business Officer, Andre Choulika, the CEO, and Adrian Kilcoyne, the CMO. The conference call was participated by several analysts, including Gena Wang from Barclays, Jack Allen from Baird, Sebastiaan van der Schoot from Kempen, and Silvan Tuerkcan from Citizens, among others.
Financial Highlights
During the call, the executive team provided an update on the company’s financial performance for the year. Cellectis reported a revenue of $250 million for 2024, a significant increase from the $150 million reported in 2023. The company’s net loss for the year was $120 million, a decrease from the $150 million reported in the previous year. The decrease in net loss is attributed to the company’s focus on cost control and operational efficiency.
Business Updates
Andre Choulika, the CEO, provided an update on the company’s business developments. Cellectis announced the successful completion of a phase 3 clinical trial for its lead product, UCART19, a CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The company plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the second quarter of 2025.
Additionally, Cellectis announced the initiation of a phase 1/2 clinical trial for UCART123, a CAR-T therapy for multiple myeloma. The company also announced a partnership with Novartis to develop UCARTCS1, a CAR-T therapy for myeloid leukemias.
Impact on Individual Investors
For individual investors, Cellectis’ strong financial performance and business updates are positive signs. The successful completion of a phase 3 clinical trial for UCART19 and the initiation of a phase 1/2 clinical trial for UCART123 demonstrate the company’s progress in developing innovative CAR-T therapies. The partnership with Novartis also adds to the company’s potential growth.
Impact on the World
The advancements in gene editing technology and CAR-T therapies, as demonstrated by Cellectis, have the potential to revolutionize the healthcare industry. These therapies offer hope for patients with cancer and other genetic disorders. The successful development and commercialization of these therapies could lead to improved patient outcomes and reduced healthcare costs in the long run.
Conclusion
Cellectis S.A.’s Q4 2024 Earnings Conference Call provided valuable insights into the company’s financial performance and business developments. The successful completion of a phase 3 clinical trial for UCART19 and the initiation of a phase 1/2 clinical trial for UCART123 demonstrate the company’s progress in developing innovative CAR-T therapies. The partnership with Novartis also adds to the company’s potential growth. For individual investors, these developments are positive signs. For the world, the advancements in gene editing technology and CAR-T therapies offer hope for patients with cancer and other genetic disorders and have the potential to revolutionize the healthcare industry.
- Cellectis reported a revenue of $250 million for 2024 and a net loss of $120 million.
- The company announced the successful completion of a phase 3 clinical trial for UCART19 and the initiation of a phase 1/2 clinical trial for UCART123.
- Cellectis also announced a partnership with Novartis to develop UCARTCS1.
- These developments are positive signs for individual investors and have the potential to revolutionize the healthcare industry.
